Translational research for hepatocellular carcinoma: What’s new?


Submitted: 11 July 2017
Accepted: 27 July 2017
Published: 30 October 2017
Abstract Views: 797
PDF: 544
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Hepatocellular carcinoma (HCC) is a heterogeneous disease that usually develops within liver cirrhosis. Cancerogenesis in HCC is not a clear process and, at present, there is not a well-defined sequence of DNA mutations able to explain the entire process, from normal hepatocyte to HCC. Lately, the impact of some oncogenes on HCC development has been studied and some of these genes belong to the MAPKinases pathway, highlighting the importance of downstream effectors stimulated by the interaction between extracellular growth factors and tyrosine kinase receptors. Unfortunately, drugs able to interfere with the aforementioned pathway showed no positive results in clinical trials. A number of preclinical studies have focused the attention on epigenetic changes in HCC cells, focusing on the extensive DNA hypermetilation as a factor causing the knockout of several tumor suppressor genes. Cancerogenesis of HCC, at least at an early phase, could be sustained by epigenetic changes. Finally, some authors have tried to classify HCC on the basis of gene mutations found after performing an extensive genome sequencing, and interestingly, they have identified different classes of HCC on the basis of different clusters of mutated genes. HCC is not characterized by a unique driver mutation, as the case of EGFR mutations for lung cancer or K-Ras mutations for colorectal cancer, thus it is, at present, very difficult to identify a reliable target for antitumoral therapy. This review focuses on current translational research and molecular targets in the treatment of HCC.

Supporting Agencies

Holling Cancer Center's K12 Paul Calebresi Clinnical and Translational Oncology Training Program K12 CA157688

Pisconti, S., Gnoni, A., Della Vittoria Scarpati, G., Licchetta, A., Silvestris, N., Giuliano, M., Montrone, M., Addeo, R., Perri, F., & Giordano, A. (2017). Translational research for hepatocellular carcinoma: What’s new?. Translational Medicine Reports, 2(1). https://doi.org/10.4081/tmr.6902

Downloads

Download data is not yet available.

Citations